2 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMOPending
Our first aim is to evaluate the validity of the developed arm leg ergometer prototype during an incremental exercise test by comparing the outcomes with a regular bicycle ergometer test. The second objective is to describe the movement of…